As the economy is recovering, the vaccination program and the stimulus measures implemented by the Biden administration are supporting the rapid recovery, with stock indexes fluctuating close to their all-time highs.
Last week, official data showed that US companies had hired the most workers in 10 months in June, increasing wages and providing incentives to attract millions of unemployed back to work. The nonfarm payrolls rose 850,000 jobs in June, higher than the expected increase to 700,000. In May, the economy added 583,000 jobs. President Joe Biden said:
“This is historic progress, pulling our economy out of the worst crisis in 100 years, driven in part by our dramatic progress in vaccinating our nation and beating back the pandemic as well as other elements of the American Rescue Plan.”
Meanwhile, new orders for U.S.-made goods bounced back in May. The US Commerce Department said that factory orders jumped 1.7%, after falling 0.1% in April. Economists expected the indicator to increase by 1.6%. Orders rose 17.2% on a year-on-year basis. The report is relevant since manufacturing accounts for almost 12% of the US economy.
OTC stocks are benefiting from a healthier labor market and manufacturing industry. As of today, the OTCQX Composite index is fluctuating near its all-time high.
For investors, we preach the key to trading hot OTC stocks is finding momentum BEFORE it happens and then be patient.
Today, we’ll look at 4 hot OTC stocks that will greatly reward patient investors. They are 88 Energy Limited (OTCMKTS: EEENF), Enzolytics Inc. (OTCPK: ENZC), Majic Wheels Corp. (OTCPK: MJWL), and Regen BioPharma, Inc. (OTCPK: RGBP).
We always alert our subscribers first before we publish for our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here. We alert our subscribers with our best ideas before our regular readers.
If you watch the Insider Financial YouTube channel, you can get a sense of the ideal time to book profits. We warned our subscribers not to get greedy or get caught up in the diamond hands/paper hands BS.
We also recommend you own a portfolio of OTC stocks. For some, that can be as many as 10 to 20 or more OTC stocks. This provides diversification and allows one to manage the market’s moods much easier. It also helps to own shares in the following 4 hot OTC stocks gaining momentum.
Hot OTC Stocks to Watch #1 EEENF
Since our latest update on 88 Energy Limited, the company has made some good progress, reinforcing our bullish stance on the OTC stock. The share price rose over 21% on Friday and has gained over 60% since last Monday, reaching the highest level since the beginning of April. EEENF is now trading at $0.034, up from two cents at the end of June, but still far from the year-to-date peak at $0.08 reached on April 5.
Insider Financial shared its take on the OTC stock in mid-March, well before the YTD high, which proves once again the great value of subscribing with us and accessing the best OTC stock picks.
88 Energy focuses on the exploration of oil and gas properties in Alaska and is now very close to confirming the existence of oil in one of its fully owned sites. It currently holds a 59% working interest in the Icewine project, which covers an area of about 231,000 acres, and a 100% working interest in the Yukon Gold leases with an area of 15,235 acres. It used to have a 50% working interest in the Peregrine project, with an area of about 195,373 acres, but it recently acquired the other half and is now the sole owner of Peregrine, which is a hot project these days.
Last year, the company announced that it would test the Merlin exploration well by drilling. In March 2021, it launched operations and confirmed the potential existence of hydrocarbon-bearing zones at the site, which is part of the Peregrine Project. In April, the EEENF share price surged after the company announced the existence of multiple potentially hydrocarbon-bearing zones.
At the end of May, 88 Energy confirmed that it had substantial evidence of oil in downhole samples analyzed in the laboratory, but the data was in raw format and required further investigation. More conclusive reports came last month. On June 24, the company said that geochemical analysis of fluid extracts from selected core samples definitively demonstrated the presence of hydrocarbons. Next, EEENF will continue with the quantitative screening on remaining samples and start phase two of side-wall core trim analysis, including: quantitative extraction, SARA, isotopes, and biomarker analysis.
EEENF prepared a chart showing the samples taken during drilling and related testing program and results received to date and or pending to be received.
On July 1, the company confirmed that it fully repaid all of its debt after completing the sale transaction for its Alaskan Oil and Gas Tax Credits. $16.1 million of $18.7 million sale proceeds were applied to full repayment of outstanding debt. The company is now debt free with cash holdings of 14.8 million Australian dollars (unaudited) as of 30 June 2021.
EEENF’s moves suggest that the company is really onto something.
$EEENF How many more hints you need? (1) Getting rid the of partner and owning it 100% (2) selling tax credits and clearing debt (3) ESG approval (like FDA) and today Lance dropping that 3Billion nugget. We know what’s coming.
— Akshat Bhatia 🇺🇸 (@OfficiallyAKB) June 30, 2021
EEENF’s largest shareholders include subsidiaries of Merrill Lynch, Citigroup, BNP Paribas, and JPMorgan, which wouldn’t hold the stock if there was no potential. The top 20 shareholders increased their stake from 36% to 64%. Meanwhile, the company’s managing director, Dave Wall, has doubled his position from 120 million shares to 240 million shares.
We remain bullish on EEENF and see new highs sooner than later.
Hot OTC Stocks to Watch #2 ENZC
Enzolytics Inc. is one of the companies that we think can turn into something big thanks to its HIV therapy and other drugs. You can buy ENZC shares for $0.20, down 33% from the beginning of June. The share price peaked in February at over 80 cents and has corrected since then.
We shared our bullish sentiment on ENZC last October at just $.014 a share. We think this is a good time to include ENZC in your portfolio, as the OTC stock is undervalued and a discount entry opportunity at these levels.
Enzolytics has been working on some unique therapies that can support its value in the long term. The company patented anti-HIV therapeutics and applies its proprietary methodology to produce human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. ENZC has tested its anti-HIV therapeutics and has developed a proprietary cell line that generates human monoclonal antibodies that neutralize HIV.
For those unfamiliar, monoclonal antibodies are laboratory-made protein that mimics our immune system’s capability to fight off viruses and other pathogens. It is produced by cloning a unique white blood cell.
At the end of last year, Enzolytics merged with BioClonetics Immunotherapeutics, Inc., driving share prices to new highs. BioClonetics is another biotech firm that has its proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases, including HIV, influenza A, influenza B, rabies, tetanus, and diphtheria.
Recently, ENZC has been recognized by Intel Corporation for its work with monoclonal antibodies, when the tech giant released a white paper titled “Optimizing Empathetic AI to Cure Deadly Diseases,” focusing on ENZC’s potential to use artificial intelligence (AI) technology in the development of monoclonal antibodies.
Meanwhile, ENZC has made some progress in developing monoclonal antibodies that can target all types of HTLV-1 virus, which causes a rare form of cancer. Viruses are known to produce mutations, which make the use of specific monoclonal antibodies less efficient or inefficient at all. For example, there have been identified over 6,000 strains of HIV-1. Thanks to AI, ENZC can identify specific sites on the virus that are neutralizable and most importantly immutable, which would enable it to develop monoclonal antibodies targeting those sites and thus showing efficiency against all potential variants. The company announced that it conserved expectedly immutable sites on the HTLV-1 virus against which it will produce targeted anti-HTLV-1 monoclonal antibodies. Today, there are no effective vaccines against HTLV-1 and no antiviral drugs available for treating infections caused by the virus. The same approach can be used for HIV-1 and even against the virus causing COVID-19, so we’re talking about a potentially game-changing approach.
In mid-June, ENZC said that it had concluded definitive plans to advance its previously tested ITV-1 anti-HIV therapeutics to clinical trials and distribution throughout Europe. Completion of these steps will establish its anti-HIV therapy as a significant revenue source for the company.
We believe ENZC is one of the best OTC stocks to hold with a long-term target.
Hot OTC Stocks to Watch #3 MJWL
Majic Wheels Corp. continues to extend its rally, currently trading at the highest level on record at $0.25, up 71% during the last five days. At the beginning of June, when we paid attention to MJWL, you could buy the OTC stock for $0.054 per share. Since the beginning of the year, the OTC stock has already increased by an incredible 14,000%.
We anticipated this bullish move, but it still makes sense to buy MJWL, as the company has the potential to grow bigger by leveraging the cryptocurrency trend. We see MJWL as one of the most-underrated and underappreciated plays on the OTC Markets.
We have no idea why it's number 21 on most read boards on iHub.https://t.co/Y8DBGhUj37
It should be number 1!
Look at this chart! pic.twitter.com/g3Z0WZ7xHM
— Insider Financial (@InsidrFinancial) July 2, 2021
Previously, Majic Wheels used to operate in the waste management sector, but it discontinued those operations and instead focused on fintech and software markets. In mid-May, MJWL appointed David Chong as new CEO and director, and it also applied for OTCIQ to become OTC Pink Current. The refreshed business focuses on fintech and software through M&As.
At the end of the same month, MJWL announced its intention to acquire CGCX Ltd, a cryptocurrency exchange and custody service platform generating $150 million in revenue. In April, CGCX launched its first insured over-the-counter (OTC) crypto trading desk in India, offering traders a direct medium of exchange. The company will enable Indian traders to directly buy and sell digital assets from a dedicated trading desk as individuals or as an institution. On June 30, MJWL said the acquisition had been completed, and the share price has surged since then.
Meanwhile, Majic said that it had been granted OTCIQ Access after completing the required verifications.
The company is transparent, ambitious, and operates in the fastest-growing industry. It can really turn into something big. We presented our bull case for MJWL in a recent post.
Hot OTC Stocks to Watch #4 RGBP
Regen BioPharma, Inc. is a tiny biotech firm that has the potential to become a major pharma player. RGBP is in a bullish mood right now, gaining 32% during the last five days to $0.023. The OTC stock has gained over 3,000% since the beginning of the year, and still has much room for growth.
RGBP is an OTC stock to hold for months to leverage the price ascension as the company monetizes its patents and therapies.
Regen focuses on translational medicine platforms for the commercialization of stem cell therapies. Stem cells are special cells that can develop into any type of human cells, which opens new possibilities in therapeutics. RGBP, which is still not Pink Current, has been working on getting regulatory approval and conduct clinical trials in cell therapy. The company produces stem-based medicines for diabetes, heart-related illness, circulatory issues, and Chronic Obstructive Pulmonary Disease. The stem cell industry is expected to exceed $15 billion by 2027.
Meanwhile, Regen is also working on small molecules capable of targeting cancer and autoimmunity.
Recently, Regen signed two deals with Oncology Pharma, a leader in oncology treatments. One deal focuses on treating pancreatic cancer, and the other one is for the treatment of colon cancer.
At the beginning of May, Oncology Pharma entered into a licensing agreement with Regen to use its technology related to small molecules to activate immune checkpoints for the treatment of colon cancer.
Some investors have speculated that a Regen-Oncology merger was just around the corner. Precigen has also been rumored to be a potential acquirer of RGBP. However, no official announcement has been released. Still, Regen is a good OTC stock to buy on its own. It has dozens of regulatory filings, over 20 patents, and several ongoing clinical trials.
On July 2, Regen filed an 8-K report with the Securities and Exchange Commission (SEC), announcing that its wholly-owned subsidiary KCL Therapeutics, Inc. was informed by the United States Patent and Trademark Office (USPTO) that patent protection shall be granted to KCL with regard to “methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition.” The news triggered the price ascension on Friday, propelling the OTC stock closer to its YTD at six cents.
THE FINAL NOTE
Today is a great opportunity to benefit from the stock market’s bullishness and invest in OTC stocks with great potential during a reviving economy. Our job is to identify the best OTC stock alerts with strong fundamentals and let our subscribers pick the ones they like to build a well-diversified portfolio oriented at penny stocks.
All of the 4 OTC stocks discussed today are on the rise and are good stocks to hold. Nevertheless, our best advice is to be patient and enter the market during corrections. Buying dips and selling rips as swing trades remains the best strategy in the penny stock market. Still, whenever an OTC stock is in the middle of a bull run, we recommend our subscribers to book profits.
It’s very important to eye OTC stocks that have room for growth and have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.
Remember, all you need is one or two OTC stocks to succeed in order to crush the market averages.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.